Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
Michael Kreuter(Heidelberg University), Toby M. Maher(Imperial College London), Derek Weycker(Policy Analysis (United States)), Argyrios Tzouvelekis(Yale University), Mark Atwood(Policy Analysis (United States)), Philip L. Molyneaux(Guy's and St Thomas' NHS Foundation Trust), Joyce Lee(Inserm), Klaus-Uwe Kirchgaessler(Roche (Switzerland)), Justin M. Oldham(University of Michigan)
American Journal of Respiratory and Critical Care Medicine
January 12, 2021
Cited by 198
Related Papers
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2006|1.3k
Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: Test Properties and Minimal Clinically Important Difference
|American Journal of Respiratory and Critical Care Medicine|2011|523
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Pulmonary fibrosis secondary to COVID-19: a call to arms?
|The Lancet Respiratory Medicine|2020|498
Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis: Test Validation and Minimal Clinically Important Difference
|American Journal of Respiratory and Critical Care Medicine|2010|457